Azelaic Acid 15%

There is a particular kind of frustration that comes with finding a skincare product that genuinely works for you, only to have it yanked away. For the patients who relied on Apostrophe’s Azelaic Acid 15% cream, March 2025 delivered exactly that gut punch when Hims & Hers — the parent company that had acquired Apostrophe for a cool $190 million in 2021 — decided to shutter the entire platform to focus on its booming weight loss business. The prescription skincare equivalent of your favorite restaurant closing to become a juice bar.

But before the obituary, the formula itself deserves its due. Apostrophe’s Azelaic Acid 15% was a compounded prescription cream that combined two dermatological heavyweights: azelaic acid at full prescription strength and niacinamide at a clinically relevant 4%. The pairing was smart. Azelaic acid does the heavy lifting — killing acne-causing bacteria, normalizing the rate at which skin cells shed inside pores, and inhibiting tyrosinase to fade dark spots. Niacinamide reinforces from the flanks, calming inflammation, reducing sebum production, and strengthening the moisture barrier so the azelaic acid can do its work without leaving the skin compromised.

The vehicle was deliberately minimal. Aloe vera juice as the primary soothing agent, caprylic/capric triglycerides for a touch of emollience, tocopheryl acetate for antioxidant backup, and phenoxyethanol as the sole preservative. No fragrance, no unnecessary botanical extracts, no Instagram-friendly but dermatologically questionable additions. This was a formula designed by dermatologists who wanted their patients to use it consistently without their skin throwing a fit.

Application was straightforward. The white cream dispensed from an airless pump — a thoughtful packaging choice that prevented contamination and ensured consistent dosing. It spread easily without dragging and absorbed within about a minute, leaving behind a matte, barely-there finish that layered well under moisturizer and sunscreen. The initial tingling that most azelaic acid users experience was present but manageable, typically subsiding within the first two weeks of use.

Where this product truly earned its following was in the combination of conditions it could address simultaneously. A patient dealing with hormonal acne along the jawline and lingering dark spots from previous breakouts could treat both with a single product, applied once or twice daily. Someone with mild rosacea and occasional breakouts found that the dual anti-inflammatory action of azelaic acid and niacinamide calmed both concerns without the irritation that retinoids or benzoyl peroxide might trigger. And critically, this was one of the few prescription-strength options safe for use during pregnancy — a gap that few other actives could fill.

The clinical evidence supporting 15% azelaic acid is robust and spans decades. Studies have demonstrated comparable efficacy to adapalene 0.1% for acne with significantly less irritation, meaningful improvements in papulopustular rosacea rivaling metronidazole, and measurable lightening of post-inflammatory hyperpigmentation. The addition of niacinamide at 4% was not merely trendy; multiple controlled trials have shown niacinamide’s ability to reduce sebum excretion, improve skin barrier function, and provide its own independent brightening effect through inhibition of melanosome transfer.

The limitations were real, however. Azelaic acid at any concentration is not a fast worker. Users expecting the rapid visible peeling of a retinoid or the overnight bacterial knockout of benzoyl peroxide found azelaic acid’s gradual, steady approach frustrating. Eight to twelve weeks for meaningful acne improvement, potentially sixteen or more for significant pigmentation fading — that is a long time to wait, especially when you are paying a subscription premium for the privilege.

And the cost was the elephant in the room. Apostrophe’s teledermatology model — consultation fee plus ongoing prescription costs — placed this compounded cream at a significant markup over what a patient might pay for generic azelaic acid gel through traditional channels with insurance. The convenience of skipping the dermatologist’s office was genuine, but convenience has always been an expensive luxury in healthcare.

The texture and user experience, while pleasant, were nothing remarkable. This was a workmanlike cream that did its job without fanfare. It did not have the elegant sensory profile of a Korean beauty serum or the satisfying slip of a high-end treatment. It was clinical in the best and most literal sense — effective, unembellished, and focused entirely on outcomes.

For the patients who found their rhythm with this product — who had navigated the initial tingling, waited through the slow weeks, and finally arrived at clearer, more even-toned skin — the brand’s closure was a genuine loss. The good news is that azelaic acid at 15% is available through other channels, and the niacinamide can easily be added as a separate step. The formula was excellent, but the ingredients are not proprietary. What Apostrophe provided was the combination and the convenience, and while both are replaceable, the sudden disappearance reminded patients that in DTC healthcare, your prescription is only as stable as the parent company’s quarterly earnings call.

Formula